Full-Time
Posted on 5/9/2026
Biomolecular interaction analysis via BLI sensors
$90k - $120k/yr
Boston, MA, USA
In Person
| , |
Gator Bio provides instruments and reusable biosensors for biomolecular analysis using Biolayer Interferometry (BLI) technology. These tools work by detecting light interference patterns to measure how molecules like proteins and small compounds bind to one another in real time. Unlike many traditional methods, Gator Bio offers a system with reusable probes and integrated technical support to help pharmaceutical and academic researchers study reaction rates and molecular binding sites. The company's goal is to provide precise data that helps scientists accelerate the drug discovery and clinical trial process.
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Palo Alto, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
People at Gator Bio who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
401(k) Company Match
Paid Vacation
Paid Holidays
Gator Bio has launched HIS XT Probes featuring AI-designed NovoBody technology for His-tagged protein analysis. The probes use computationally designed binding proteins to deliver enhanced affinity, baseline stability and data quality for antibody characterisation and biologics research. The company describes these as industry-first probes designed specifically for protein analysis applications. The technology aims to improve performance standards in biologics research and antibody development workflows. Gator Bio is based in Palo Alto, California and Seattle.
Monod Bio and Gator Bio partner to develop next-generation biosensors for advanced life science research. News provided by. Gator Bio Gator Bio will integrate one of Monod's AI-designed NovoBody(TM) binding proteins into its industry-leading biolayer interferometry platform. NovoBody(TM) binding proteins deliver superior performance, stability, and engineerability compared to traditional monoclonal antibodies SEATTLE and PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire-PRWeb/ - Monod Bio, a leader in computational protein design, and Gator Bio, a pioneer in biolayer interferometry (BLI) technologies, today announced a partnership to integrate one of Monod's proprietary AI-designed NovoBody(TM) protein binders into Gator's biosensor platform. The collaboration combines Monod's advanced AI-based protein design technology with Gator's proven BLI platform to deliver next-generation biosensing capabilities. Under the terms of the license agreement, Monod will supply NovoBody(TM) binding proteins to Gator Bio for use in a new biosensor product offering, one of the first to incorporate an AI-designed binding molecule. Gator Bio will oversee manufacturing, sales, and marketing of the biosensor, while Monod will receive upfront, supply, and royalty payments. The product launch is anticipated in the first half of 2026. "Our collaboration with Gator Bio marks a significant milestone in the adoption of computationally designed binding proteins for biosensing applications, paving the way for broader use of NovoBody(TM) binding proteins across life science research and diagnostics," said Daniel Silva Manzano, PhD, CEO of Monod Bio. "NovoBody(TM) binding proteins are computationally designed to deliver superior stability, manufacturability, and performance compared to traditional antibodies." "At Gator Bio, we are positioned at the intersection of AI innovation and experimental validation," said Hong Tan, PhD, CEO of Gator Bio. "Our BLI instruments are a critical enabling technology for the AI protein design revolution, providing the real-time, label-free characterization that validates computationally designed molecules. By incorporating AI-designed NovoBody(TM) binding proteins into our biosensor portfolio, we are both advancing and benefiting from the AI transformation of biologics development." "This collaboration exemplifies our 'Monod Inside' business model," said Carl Walkey, PhD, VP of Business Development at Monod Bio. "By integrating NovoBody(TM) binding proteins into leading industry platforms like Gator's, we're enabling partners to rapidly bring breakthrough products to market." About Monod Bio Monod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington's Institute for Protein Design, co-founded by Daniel Silva Manzano, Alfredo Quijano-Rubio, and David Baker. The company is a leader in de novo protein design to create novel protein binders and biosensors for research use only (RUO) and in vitro diagnostic (IVD) applications. Monod Bio's proprietary AI platform enables the generation of novel proteins using in silico methods, including its NovoBody(TM) binders, to address unmet needs. Through its "Monod Inside" business model, Monod Bio partners with leading RUO and IVD organizations to bring next-generation products to market. For more information, visit http://monod.bio. About Gator Bio Gator Bio is a leading innovator in label-free biosensor technology, delivering high-performance analytical instruments for biomolecular interaction analysis. The company's biolayer interferometry (BLI) platform serves as a critical validation technology for AI-driven protein design, providing researchers with powerful tools for real-time, quantitative characterization of next-generation biologics including computationally designed proteins and antibodies. For more information, visit gatorbio.com Media Contact Sriram Kumaraswamy, Gator Bio, 1 855-208-0743, [email protected], www.gatorbio.com Nino Floro, Gator Bio, 1 6504205727, [email protected], www.gatorbio.com SOURCE Gator Bio
Gator Bio unveils novel new GeneSwift reagents revolutionizing genome titer and genome integrity analysis.
Gator Bio launches Gator® Pilot and Gator® Pivot Biolayer Interferometry systems for biotherapeutics discovery.